93964-78-4

Basic information

• Product Name: methyl N5-(aminocarbonyl)-L-ornithine monohydrochloride
• Synonyms: methyl N5-(aminocarbonyl)-L-ornithine monohydrochloride;L-citrulline methyl ester monohydrochloride
• CAS NO: 93964-78-4
• Molecular Formula: C₇H₁₅N₃O₃*ClH
• Molecular Weight: 225.67324
• EINECS: 300-925-2
• Mol File: 93964-78-4.mol
• Article Data: 5

Chemical Properties

• Appearance: /
• CAS DataBase Reference: methyl N5-(aminocarbonyl)-L-ornithine monohydrochloride(CAS DataBase Reference)
• NIST Chemistry Reference: methyl N5-(aminocarbonyl)-L-ornithine monohydrochloride(93964-78-4)
• EPA Substance Registry System: methyl N5-(aminocarbonyl)-L-ornithine monohydrochloride(93964-78-4)

Safety Data

• Hazardous Substances Data: 93964-78-4(Hazardous Substances Data)

Usage

General Description

Methyl N5-(aminocarbonyl)-L-ornithine monohydrochloride is a chemical compound that is derived from L-ornithine, an amino acid. It is a methylated form of N5-(aminocarbonyl)-L-ornithine and is usually found in the form of a white powder or crystalline solid. methyl N5-(aminocarbonyl)-L-ornithine monohydrochloride is commonly used in biochemical research and pharmaceutical applications, particularly in the synthesis of pharmaceutical drugs and in the study of metabolic pathways. It is also used as a substrate for enzymes involved in polyamine metabolism. The monohydrochloride form of this compound is the salt form, which is usually more stable and better suited for use in various applications.

Upstream product

• 67-56-1 methanol 
• 372-75-8 Citrulline 

Downstream Products

• 870487-08-4 (6S,9S)-1-amino-9-isopropyl-13,13-dimethyl-1,8,11-trioxo-12-oxa-2,7,10-triazatetradecane-6-carboxylic acid 
• 870487-09-5 tert-butyl ((S)-1-(((S)-1-((4-(hydroxymethyl)phenyl)amino)-1-oxo-5-ureidopentane-2-yl)amino)-3-methyl-1-oxobutane-2-yl)carbamate 
• 870487-10-8 tert-butyl ((5)-3-methyl-1-(((5)-1-((4-((((4-nitrophenoxy)carbonyl)oxy)methyl)phenyl)amino)-1-oxo-5-ureidopentan-2-yl)amino)-1-oxobutan-2-yl)carbamate 

Relevant articles and documents

Preliminary evaluation of PARACEST MRI agents for the detection of nitric oxide synthase

Several paramagnetic chemical exchange saturation transfer magnetic resonance imaging (PARACEST MRI) agents for the potential detection of nitric oxide synthase (NOS) have been synthesized and evaluated. These agents are based on an amino acid-or dipeptide-decorated DOTAM (1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid amide) chelator possessing either Tm3+ or Dy3+. The amino acid and dipeptide decorated DOTAMs were designed such that the terminal amino acid pendant group was l-arginine, which may be converted to l-citrulline by NOS. Preliminary evaluation has revealed that some of the l-arginine-decorated complexes are recognized and metabolized by the NOS. Differences in the CEST properties between Dy3+-metallated l-arginine-and l-citrulline-modified complexes suggest that these might be suitable for imaging of the NOS enzymatic activity.

COMPOSITION FOR THE TREATMENT OF IGF-1R EXPRESSING CANCER

The present invention relates to a method for the treatment of IGF-IR expressing cancers as well as to a compositions and a kit for said traitment. From one aspect, the invention reates to the combined use of a first antibody for the determination of the IGF-IR status of a cancer and a second antibody used as an ADC for the treatment of said cancer.

ANTIBODY-DRUG-CONJUGATE AND ITS USE FOR THE TREATMENT OF CANCER

The present invention relates to an antibody-drug-conjugate. From one aspect, the invention relates to an antibody-drug-conjugate comprising an antibody capable of binding to a Target, said antibody being conjugated to at least one drug selected from derivatives of dolastatin 10 and auristatins. The invention also comprises method of treatment and the use of said antibody-drug-conjugate for the treatment of cancer.